Moreover, CSF levels of soluble triggering receptor expressed on myeloid cells 2 (sTREM-2) [288] and the chitotriosidase (CHIT1) [289], markers for pro-inflammatory microglia [290,291], were decreased following NZ-therapy in MS patients. The gene discussed is CHIT1; the disease is myeloid sarcoma.